Effiux-mediated antibiotic resistance in Gram-positive bacteria

Reviews and Research in Medical Microbiology

Volumn 13, Issue 1, 2002, Pages 1-13

  Muñoz Bellido, Juan Luis ^a   Yagüe Guirao, Genoveva ^a   Gutiérrez Zufiaurre, Nieves ^a   Alonso Manzanares, Angeles ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Efflux pumps; Quinolones; Resistance; Staphylococcus; Streptococcus pneumoniae

Indexed keywords

ERYTHROMYCIN; MACROLIDE; MULTIDRUG RESISTANCE PROTEIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; EXOCYTOSIS; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 0036190182     PISSN: 0954139X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00013542-200201000-00001     Document Type: Review

References (101)

1. Proton-dependent multidrug efflux systems
2. Active efflux mechanisms for antimicrobial resistance
3. Multidrug resistance pumps in bacteria: Variations on a theme
4. Evidence for active efflux as the primary mechanism of resistance to ciprofloxacin in Salmonella enterica serovar typhimurium
5. Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa
6. Inhibition of the emergence of ciprofloxacin resistance in Streptococcus pneumoniae by multidrug efflux inhibitor reserpine
7. Major facilitator superfamily
8. The ABC family of multidrug transporters in microorganisms
9. The SMR family: A novel family of multidrug efflux protein involved with the efflux of lipophilic drugs
10. The multidrug efflux protein NorA is a prototype of a new family of transporters
11. A major superfamily of trans-membrane facilitators that catalyse uniport, symport and antiport
12. Membrane transport proteins: Implications of sequence comparisons
13. Study of macrolide, lincosamide, and streptogramin B antibiotics resistance in Staphylococcus aureus
14. Phenotypic expression and genetic heterogeneity of lincosamide inactivation in Staphylococcus spp.
15. Plasmid mediated pristinamycin resistance: PH1A, a pristinamycin 1A hydrolase
16. Plasmidmediated pristinamycin resistance: PACIIA, a new enzyme which modifies pristinamycin IIA
17. Novel mechanism for plasmid-mediated erythromycin resistance by pNE24 from Staphylococcus epidermidis
18. Inducible erythromycin resistance in staphylococci is en-coded by a member of the ATP-binding transport super-gene family
19. Characterization and molecular cloning of the novel macrolide-streptogramin B resistance determinant from Staphylococcus epidermidis
20. Distribution of genes encoding erythromycin ribosomal meth-ylases and an erythromycin efflux pump in epidemiologically distinct groups of staphylococci
21. Prevalence of macrolides-lincosamides-streptogramin B resistance and erm gene classes among clinical strains of staphylococci and streptococci
22. Characterization of plasmids that confer inducible resistance to 14-membered macrolides and streptogramin type B antibiotics in Staphylococcus aureus
23. A mechanism of resistance to partial macrolide and streptogramin B antibiotics in Staphylococcus aureus clinically isolated in Hungary
24. Cloning and sequencing of a plasmid-mediated erythromycin resistance determinant from Staphylococcus xylosus
25. Sequence of a staphylococcal plasmid gene, vga, encoding a putative ATP-binding protein involved in resistance to virginianmycin A-like antibiotics
26. Nucleotide sequence of a staphylococcal plasmid gene, vgb, encoding a hydrolase in-activating the B components of virginiamycin-like antibiotics
27. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY antimicrobial surveillance program, 1997-1999
28. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance Study
29. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: A 6-year population based assessment
30. Susceptibility of Grampositive cocci from 25 UK hospitals to antimicrobial agents including linezolid
31. Molecular mechanisms of resistance to commonly used non-betalactam drugs in Streptococcus pneumoniae
32. Phenotypic characterization of erythromycin resistance in strains of the genus Streptococcus isolated from clinical specimens
33. Oral antimicrobial susceptibilities of Streptococcus pyogenes recently isolated in five countries
34. Resistencia a macrólidos en Streptococcus pyogenes
35. Susceptibility of 2039 consecutive isolates of Streptococcus pyogenes from pharyngeal exudate samples: Results of a Spanish multicenter surveillance study over a one year period (1988-1999)
36. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: A common resistance pattern mediated by an efflux system
37. Studies of a novel ketolide ABT-773: Transport, binding to ribosomes and inhibition of protein synthesis in Streptococcus pneumoniae
38. Ketolides-telitromycin, an example of a new class of antibacterial agents
39. mefE is necessary for the erythromycin resistant M phenotype in Streptococcus pneumoniae
40. Characterization of a genetic element carrying the macrolide efflux gene mef(A) in Streptococcus pneumoniae
41. Molecular cloning and functional analysis of a novel macrolide resistance determinant, mefA, from Streptococcus pyogenes
42. Three diferent phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland
43. Different erythromycin resistance mechanisms in group C and group G streptococci
44. Estudio de los genes de resistencia a macrólidos en estreptococos de los grupos C y G
45. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998
46. Susceptibilities of oral and nasal isolates of Streptococcus mitis and Streptococcus oralis to macrolides and PCR detection of resistance genes
47. Cloning and characterization of a novel macrolide efflux gene, mreA, from Streptococcus agalactiae
48. Mechanisms of macrolide resistance in clinical group B Streptococci isolated in France
49. Presence of mefA and mefE genes in Streptococcus agalactiae
50. Amplification of macrolide efflux pumps msr and mef from Enterococcus faecium by polymerase chain reaction
51. A variety of grampositive bacteria carry mobile mef genes
52. Macrolide resistance genes in Enterococcus spp.
53. A Corynebacterium glutamicum gene conferring multidrug resistance in the heterogeneous host Escherichia coli
54. Identification ora new locus in Listeria monocytogenes involved in cellobiose-dependent repression of hly expression
55. A multidrugs efflux transporter in Listeria monocytogenes
56. Identification of the conjugative mef gene in clinical Acinetobacter junii and Neisseria gonorroheae isolates
57. Nomenclature for macrolide and macrolidelincosamide-streptogramin B resistance determinants
58. In vitro activities of 13 fluoroquinolones against Staphylococcus aureus isolates characterized mutations in gyrA, gyrB, grlA and norA and against wild type isolates
59. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae
60. Frecuencia de corresistencia a penicilina, macrólidos y fluoroquinolonas en Streptococcus pneumoniae
61. Efflux-mediated resístanse to fluoroquinolones in Gram-positive bacteria and the mycobacteria
62. Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter
63. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae
64. Two highly similar multidrug transporters of Bacillus subtilis whose expression is differentially regulated
65. Efflux pump-mediated quinolone resistance in gyrA, gyrB, grlA, norA wild-type Staphylococcus aureus
66. Activity of gemifloxacin against penicillin and ciprofloxacin resistnant Streptococcus pneumoniae displaying topoisomerase and efflux-mediated resistance mechanisms
67. Hidrophylicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus
68. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones
69. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus
70. A mutation in the 5′ untranslated region increases stability of norA mRNA, encoding a multidrug resistance transporter of Staphylococcus aureus
71. Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus
72. Inducible NorA-mediated multidrug resistance in Staphylococcus aureus
73. Expression of the multidrug transporter norA from Staphylococcus aureus is modified by a two component regulatory system
74. The effect of reserpine, an inhibitor of multidrug efflux pumps on in vitro susceptibilities of fluoroquinolone-resistant strains of Streptococcus pneumoniae to norfloxacin
75. Active efflux as a mechanism of resistance to ciprofloxacin In Streptococcus pneumoniae
76. Prevalence of a putative efflux mechanism among fluoroquinolone resistant clinical isolates of Streptococcus pneumoniae
77. Apparent involvement of a multidrug trasnporter in the fluoroquinolone resistance of Streptococcus pneumoniae
78. Efflux mediated resistance to fluoroquinolones in Gram-positive bacteria and the Mycobacteria
79. A convenient assay for estimating the possible involvement of efflux of fluoroquinolone by Streptococcus pneumoniae and Staphylococcus aureus: Evidence for disminished moxifloxacin, sparfloxacin and trovafloxacin efflux
80. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating form worldwide surveillance studioes during the 1997-1998 Respiratory Season
81. Inhibition of the emergence of ciprofloxacin resistanse in Streptococcus pneumoniae by the multidrug efflux inhibitor reserpine
82. Fluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci
83. Drug efflux and parC mutations are involved in fluoroquinolone resistance in viridans group streptococci
84. Active efflux of antimicrobial agents in wild-type strains of enterococi
85. Efflux-mediated multidrug resistance in Bacillus subtilis: Similarities and dissimilarities with the mammalian system
86. Two highly similar multidrug transporters of Bacillus subtilis whose expresión is differently regulated
87. Recognition of multiple drugs by a single protein: A trivial solution of an old paradox
88. A staphylococeal multidrug resistance gene product is a member of a new protein family
89. The SMR family: A novel family of multidrugs efflux proteins involved with the efflux of lipophilic drugs
90. SMR-type multidrugs resistance pumps
91. A two component multidrugs efflux pump, EbrAB, in Bacillus subtilis
92. N,N-dimetilglicylamido derivative of minocycline and 6-demethyl-6-desoxytetracycline, two new glycilcyclines highly effective against tetracycline resistant Gram-positive cocci
93. Tetracycline resistance determinants: Mechanisms of action, regulation of expression, genetic mobility, and distribution
94. Active efflux of tetracycline encoded by four genetically different resistance determinants in Escherichia coli
95. Second-site supressor mutations of inactivating substitutions at Gly247 of the tetracycline efflux protein, Tet(B)
96. Heterogeneity of tetracycline resistance determinants
97. Tetracyclines, molecular and clinical aspects
98. Nucleotide sequence and phylogeny of tet(L) tetracycline resistance determinant encoded by plasmid psTE1 from Staphylococcus hycius
99. TetZ, a new tetracycline resistance determinant discovered in Gram-positive bacteria, shows high homology to Gram-negative regulated efflux sytems
100. Recent developments in tetracycline antibiotics
101. Characterization of emeA, a norA homolog and multidrug resistance efflux pump, in Enterococcus faecalis